Keyphrases
Phase II Study
100%
Metastatic Pancreatic Cancer
100%
Gemcitabine-refractory
100%
Disease Progression
66%
Progressive Disease
66%
Gemcitabine
66%
Adverse Reactions
66%
Clinical Benefit Response
66%
Confidence Interval
33%
Symptomatic Patients
33%
Renal Function
33%
Pancreatic Cancer
33%
Antitumor Activity
33%
Twice Daily
33%
Monotherapy
33%
Informed Consent
33%
Karnofsky Performance Status
33%
Complete Response
33%
Neutropenia
33%
Response Rate
33%
Metastatic Lesions
33%
Partial Response
33%
Median Survival Time
33%
Liver Function
33%
Stable Disease
33%
Progression-free Survival
33%
Objective Response
33%
Phase II Trial
33%
Median Progression-free Survival
33%
Nave
33%
First-line Chemotherapy
33%
1-year Survival
33%
First-line Therapy
33%
Pneumonitis
33%
Pancreatic Adenocarcinoma
33%
Anorexia
33%
Antibiotic Treatment
33%
Combination Chemotherapy
33%
Rest Period
33%
Overall Survival Benefit
33%
Resectable Pancreatic Cancer
33%
Appropriate Antibiotics
33%
Gemcitabine Monotherapy
33%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
100%
Gemcitabine
100%
Diseases
50%
Adverse Event
33%
Disease Exacerbation
33%
Monotherapy
33%
Progression Free Survival
33%
Neoplasm
16%
Pneumonia
16%
Overall Survival
16%
Chemotherapy
16%
Neutropenia
16%
Survival Rate
16%
Phase II Trials
16%
First-Line Chemotherapy
16%
Median Survival Time
16%
Pancreas Adenocarcinoma
16%
Anorexia
16%